The Inhibitor Ko143 Is Not Specific for ABCG2

Multidrug resistance in cancer: role of ATP–dependent transporters

Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · see citing works

Drug-Resistant Epilepsy

Kwan, P., Schachter, S. C., & Brodie, M. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004418 · Cited by 1,113 · see citing works

Drug resistance in brain diseases and the role of drug efflux transporters

Löscher, W., & Potschka, H. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1728 · Cited by 904 · see citing works

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Allen, J. D., van Loevezijn, A., Rademaker-Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J. H. M., Koomen, G., & Schinkel, A. H. (2002) · PubMed · Cited by 690 · see citing works

[Drug-resistant epilepsy].

Arroyo, S., Rumià, J., Martínez, I., & Ribalta, T. (1998) · PubMed · Cited by 652 · see citing works

Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases

Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617 · see citing works

MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy

Tishler, D. M., Weinberg, K. I., Hinton, D. R., Barbaro, N. M., Annett, G., & Raffel, C. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb01657.x · Cited by 529 · see citing works

HIV-1 Protease Inhibitors Are Substrates for theMDR1 Multidrug Transporter

Lee, C. G. L., Gottesman, M. M., CARDARELLI, C. O., Ramachandra, M., Jeang, K., Ambudkar, S. V., Pastan, I. H., & Dey, S. (1998) · Biochemistry · doi:10.1021/bi972709x · Cited by 477 · see citing works

Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity

Robey, R. W., Honjo, Y., Morisaki, K., Nadjem, T., Runge, S., Risbood, M., Poruchynsky, M. S., & Bates, S. E. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601370 · Cited by 367 · see citing works

Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs

Matsson, P., Pedersen, J. M., Norinder, U., Bergström, C. A. S., & Artursson, P. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9896-0 · Cited by 318 · see citing works

Quantitative Membrane Protein Expression at the Blood–Brain Barrier of Adult and Younger Cynomolgus Monkeys

Ito, K., Uchida, Y., Ohtsuki, S., Aizawa, S., Kawakami, H., Katsukura, Y., Kamiie, J., & Terasaki, T. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22487 · Cited by 231 · see citing works

ABCG2: structure, function and role in drug response

Polgár, O., Robey, R. W., & Bates, S. E. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.1.1 · Cited by 222 · see citing works

P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study

Feldmann, M., Asselin, M., Liu, J. Y. W., Wang, S., McMahon, A. W., Anton‐Rodriguez, J., Walker, M. D., Symms, M. R., Brown, G. D., Hinz, R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70109-1 · Cited by 181 · see citing works

The “Specific” P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)

Kannan, P., Telu, S., Shukla, S., Ambudkar, S. V., Pike, V. W., Halldin, C., Gottesman, M. M., Innis, R. B., & Hall, M. D. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100078a · Cited by 181 · see citing works

Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications

Kannan, P., John, C. S., Zoghbi, S. S., Halldin, C., Gottesman, M. M., Innis, R. B., & Hall, M. D. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.138 · Cited by 167 · see citing works

Role Reversal for Anticancer Agents

Pardee, A. B. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.4.22 · Cited by 165 · see citing works

Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar

Kühnle, M., Egger, M. E., Müller, C., Mahringer, A., Bernhardt, G., Fricker, G., König, B., & Buschauer, A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8013822 · Cited by 158 · see citing works

Neuropathology of the blood–brain barrier and pharmaco-resistance in human epilepsy

Liu, J. Y. W., Thom, M., Catarino, C. B., Martinian, L., Figarella-Branger, D. F., Bartoloméi, F., Koepp, M. J., & Sisodiya, S. M. (2012) · Brain · doi:10.1093/brain/aws147 · Cited by 141 · see citing works

P-Glycoprotein Function at the Blood–Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-Desmethyl-Loperamide

Kreisl, W. C., Liow, J., Kimura, N., Seneca, N. M., Zoghbi, S. S., Morse, C. L., Herscovitch, P., Pike, V. W., & Innis, R. B. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.070151 · Cited by 131 · see citing works

The Calcium Channel Blockers, 1,4-Dihydropyridines, Are Substrates of the Multidrug Resistance-Linked ABC Drug Transporter, ABCG2

Shukla, S., Robey, R. W., Bates, S. E., & Ambudkar, S. V. (2006) · Biochemistry · doi:10.1021/bi060552f · Cited by 103 · see citing works

Altered P-Glycoprotein Expression in AIDS Patients with HIV Encephalitis

Langford, D., Grigorian, A., Rosemary, H., Adame, A., Ellis, R. J., Hansen, L. A., & Masliah, E. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.10.1038 · Cited by 89 · see citing works

Vascular colocalization of P‐glycoprotein, multidrug‐resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies

Sisodiya, S. M., Martinian, L., Scheffer, G. L., van der Valk, P., Scheper, R. J., Harding, B. N., & Thom, M. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00699.x · Cited by 89 · see citing works

(R)-[11C]verapamil is selectively transported by murine and human P-glycoprotein at the blood–brain barrier, and not by MRP1 and BCRP

Römermann, K., Wanek, T., Bankstahl, M., Bankstahl, J. P., Fedrowitz, M., Müller, M., Löscher, W., Kuntner, C., & Langer, O. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.05.012 · Cited by 71 · see citing works

Evidence for the Role of Glycosylation in Accessibility of the Extracellular Domains of Human MRP1 (ABCC1)

Müller, M., Yong, M., Peng, X.-H., Petre, B., Arora, S., & Ambudkar, S. V. (2002) · Biochemistry · doi:10.1021/bi026075s · Cited by 55 · see citing works

Use of the Cassette-Dosing Approach to Assess Brain Penetration in Drug Discovery

Liu, X., Ding, X., Deshmukh, G. S., Liederer, B. M., & Hop, C. E. C. A. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.044420 · Cited by 55 · see citing works

A Novel PET Protocol for Visualization of Breast Cancer Resistance Protein Function at the Blood–Brain Barrier

Wanek, T., Kuntner, C., Bankstahl, J. P., Mairinger, S., Bankstahl, M., Stanek, J., Sauberer, M., Filip, T., Erker, T., Müller, M., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.112 · Cited by 53 · see citing works

A Dual-Fluorescence High-Throughput Cell Line System for Probing Multidrug Resistance

Brimacombe, K. R., Hall, M. D., Auld, D. S., Inglese, J., Austin, C. P., Gottesman, M. M., & Fung, K.-L. (2009) · Assay and Drug Development Technologies · doi:10.1089/adt.2008.165 · Cited by 52 · see citing works

N-desmethyl-Loperamide Is Selective for P-Glycoprotein among Three ATP-Binding Cassette Transporters at the Blood-Brain Barrier

Kannan, P., Brimacombe, K. R., Zoghbi, S. S., Liow, J., Morse, C. L., Taku, A. K., Pike, V. W., Halldin, C., Innis, R. B., Gottesman, M. M., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031161 · Cited by 51 · see citing works

Radioligands targeting P‐glycoprotein and other drug efflux proteins at the blood–brain barrier

Wanek, T., Mairinger, S., & Langer, O. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2993 · Cited by 50 · see citing works

Overlapping Substrate and Inhibitor Specificity of Human and Murine ABCG2

Bakhsheshian, J., Hall, M. D., Robey, R. W., Herrmann, M. A., Chen, J., Bates, S. E., & Gottesman, M. M. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.053140 · Cited by 49 · see citing works

Bioluminescent imaging of drug efflux at the blood–brain barrier mediated by the transporter ABCG2

Bakhsheshian, J., Wei, B., Chang, K.-E., Shukla, S., Ambudkar, S. V., Simpson, R. J., Gottesman, M. M., & Hall, M. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312159110 · Cited by 48 · see citing works

Rapid detection of ABC transporter interaction: Potential utility in pharmacology

Robey, R. W., Lin, B., Qiu, J., Chan, L. L., & Bates, S. E. (2010) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2010.11.003 · Cited by 41 · see citing works

Radiosynthesis of [2-11C-carbonyl]dantrolene using [11C]phosgene for PET

Takada, Y., Ogawa, M., Suzuki, H., & Fukumura, T. (2010) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2010.03.012 · Cited by 24 · see citing works

Use of Cassette Dosing Approach to Examine the Effects of P-Glycoprotein on the Brain and Cerebrospinal Fluid Concentrations in Wild-Type and P-Glycoprotein Knockout Rats

Liu, X., Cheong, J., Ding, X., & Deshmukh, G. S. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.055590 · Cited by 23 · see citing works

Factors That Limit Positron Emission Tomography Imaging of P-Glycoprotein Density at the Blood–Brain Barrier

Kannan, P., Pike, V. W., Halldin, C., Langer, O., Gottesman, M. M., Innis, R. B., & Hall, M. D. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400011g · Cited by 21 · see citing works

Radiosynthesis of N5‐[18F]fluoroacetylornithine (N5‐[18F]FAO) for PET imaging of ornithine decarboxylase (ODC) in malignant tumors

Turkman, N., Gelovani, J. G., & Alauddin, M. M. (2010) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.1799 · Cited by 11 · see citing works

Synthesis and ABCG2 Inhibitory Activity of Novel Fumitremorgin C Analogs – Specificity and Structure Activity Correlations

Szolomájer‐Csikós, O., Beéry, E., Kosa, L., Rajnai, Z., Jani, M., Hetényi, A., Jakab, K. T., Krajcsi, P., & Tóth, G. K. (2013) · Medicinal Chemistry · doi:10.2174/1573406411309040003 · Cited by 10 · see citing works

BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.

Liu, Z., L'Heureux, F., Pouliot, J., Heckel, A., Bamberger, U., & Georges, E. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09296-x · Cited by 8 · see citing works

Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection

Zander, S. A. L., Beijnen, J. H., & van Tellingen, O. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2012.11.003 · Cited by 6 · see citing works

Structural basis of small-molecule inhibition of human multidrug transporter ABCG2

Jackson, S. M., Manolaridis, I., Kowal, J., Zechner, M., Taylor, N. M. I., Bause, M., Bauer, S., Bartholomäus, R., Bernhardt, G., König, B., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0049-1 · Cited by 325 · see citing works

Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance

Xiao, H., Zheng, Y., Ma, L., Tian, L., & Sun, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648407 · Cited by 264 · see citing works

ABCC1 transporter exports the immunostimulatory cyclic dinucleotide cGAMP

Maltbaek, J. H., Cambier, S., Snyder, J. M., & Stetson, D. B. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.006 · Cited by 131 · see citing works

Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators

Zattoni, I. F., Delabio, L. C., Dutra, J. D. P., Kita, D. H., Scheiffer, G., Hembecker, M., Pereira, G. D. S., Moure, V. R., & Valdameri, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114346 · Cited by 88 · see citing works

The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells

Yin, W., Xiang, D., Wang, T., Zhang, Y., Pham, C. V., Zhou, S., Jiang, G.-Q., Hou, Y., Zhu, Y., Han, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89931-9 · Cited by 86 · see citing works

GSH and Ferroptosis: Side-by-Side Partners in the Fight against Tumors

Jiang, Y., Glandorff, C., & Sun, M. (2024) · Antioxidants · doi:10.3390/antiox13060697 · Cited by 84 · see citing works

Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism

Yu, Q., Ni, D., Kowal, J., Manolaridis, I., Jackson, S. M., Stahlberg, H., & Locher, K. P. (2021) · Nature Communications · doi:10.1038/s41467-021-24651-2 · Cited by 80 · see citing works

Small‐molecule inhibitors of multidrug resistance‐associated protein 1 and related processes: A historic approach and recent advances

Stefan, S. M., & Wiese, M. (2018) · Medicinal Research Reviews · doi:10.1002/med.21510 · Cited by 77 · see citing works

Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein

Weidner, L. D., Fung, K.-L., Kannan, P., Moen, J. K., Kumar, J. S., Mulder, J., Innis, R. B., Gottesman, M. M., & Hall, M. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067785 · Cited by 70 · see citing works

ABCG2/BCRP: Specific and Nonspecific Modulators

Peña‐Solórzano, D., Stark, S., König, B., Sierra, C. A., & Ochoa‐Puentes, C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21428 · Cited by 70 · see citing works

Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2)

Spindler, A., Stefan, K., & Wiese, M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00035 · Cited by 68 · see citing works

9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein

Stefan, K., Stefan, S. M., & Wiese, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00788 · Cited by 67 · see citing works

A review of synthetic bioactive tetrahydro-β-carbolines: A medicinal chemistry perspective

Wang, J., Gong, F., Liang, T., Xie, Z., Yang, Y.-X., Cao, C., Gao, J., Lu, T., & Chen, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113815 · Cited by 61 · see citing works

Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers

Chang, C., Wang, Y., Zalath, M. B., Liu, D., Cardillo, T. M., & Goldenberg, D. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0219 · Cited by 61 · see citing works

Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2)

Krapf, M. K., Gallus, J., & Wiese, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.020 · Cited by 53 · see citing works

Targeting Glucose Metabolism in Cancer Cells as an Approach to Overcoming Drug Resistance

Cunha, A., Silva, P. M. A., Sarmento, B. F. C. C., & Queirós, O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112610 · Cited by 56 · see citing works

Maternal malnutrition impacts placental morphology and transporter expression: an origin for poor offspring growth

Connor, K. L., Kibschull, M., Matysiak‐Zablocki, E., Nguyen, T. T.-T. N., Matthews, S. G., Lye, S. J., & Bloise, E. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.108329 · Cited by 52 · see citing works

4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2)

Krapf, M. K., Gallus, J., & Wiese, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00441 · Cited by 51 · see citing works

A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity

Barghout, S. H., Aman, A. M., Nouri, K., Blatman, Z., Arevalo, K., Thomas, G. E., MacLean, N., Hurren, R., Ketela, T., Saini, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141518 · Cited by 50 · see citing works

ABCG2 influence on the efficiency of photodynamic therapy in glioblastoma cells

Müller, P., Abdel Gaber, S. A., Zimmermann, W., Wittig, R., & Stepp, H. (2020) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2020.111963 · Cited by 49 · see citing works

Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs

Wu, C., Hsiao, S.-H., Huang, Y.-H., Hung, L.-C., Yu, Y.-J., Chang, Y., Hung, T., & Wu, Y. (2020) · Cancers · doi:10.3390/cancers12010195 · Cited by 48 · see citing works

Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2

Wu, C., Hsiao, S.-H., & Wu, Y. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101011 · Cited by 47 · see citing works

Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells

Abdelfatah, S., Böckers, M., Asensio, M., Kadioglu, O., Klinger, A., Fleischer, E., & Efferth, T. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153196 · Cited by 47 · see citing works

2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2

Krapf, M. K., Gallus, J., Namasivayam, V., & Wiese, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01011 · Cited by 46 · see citing works

Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades

Paškevičiūtė, M., & Petrikaitė, V. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0584-7 · Cited by 46 · see citing works

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance

Wu, Z., Yang, Y., Teng, Q., Wang, J., Lei, Z., Wang, J.-Q., Lusvarghi, S., Ambudkar, S. V., Yang, D., & Chen, Z. (2020) · Cancers · doi:10.3390/cancers12010186 · Cited by 46 · see citing works

Synthesis and biological evaluation of quinazoline derivatives – A SAR study of novel inhibitors of ABCG2

Krapf, M. K., Gallus, J., Spindler, A., & Wiese, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.026 · Cited by 45 · see citing works

New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold

Krapf, M. K., Gallus, J., Vahdati, S., & Wiese, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01012 · Cited by 44 · see citing works

Discovery of Novel Flavonoid Dimers To Reverse Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediated Drug Resistance in Cancers Using a High Throughput Platform with “Click Chemistry”

Wong, I. L. K., Zhu, X., Chan, K., Law, M. C., Lo, A. M. Y., Hu, X., Chow, L. M. C., & Chan, T. H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00834 · Cited by 43 · see citing works

Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

Wu, C., Hung, T., Hsiao, S.-H., Huang, Y.-H., Hung, L.-C., Yu, Y.-J., Chang, Y., Wang, S.-P., & Wu, Y. (2020) · Cancers · doi:10.3390/cancers12061366 · Cited by 43 · see citing works

Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors

Zhu, X., Wong, I. L. K., Chan, K., Cui, J., Law, M. C., Chong, T. C., Hu, X., Chow, L. M. C., & Chan, T. H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00963 · Cited by 42 · see citing works

Marine Natural Products as Models to Circumvent Multidrug Resistance

Long, S., Sousa, E., Kijjoa, A., & Pinto, M. M. M. (2016) · Molecules · doi:10.3390/molecules21070892 · Cited by 41 · see citing works

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro

Yang, Y., Ji, N., Teng, Q., Cai, C., Wang, J., Wu, Z., Lei, Z., Lusvarghi, S., Ambudkar, S. V., & Chen, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00700 · Cited by 41 · see citing works

The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs

Wu, C., Hung, T., Lusvarghi, S., Chu, Y.-H., Hsiao, S.-H., Huang, Y.-H., Chang, Y., & Ambudkar, S. V. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114516 · Cited by 41 · see citing works

Metabolism of KO143, an ABCG2 inhibitor

Liu, K., Zhu, J., Huang, Y., Li, C., Lu, J., Sachar, M., Li, S., & Ma, X. (2017) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.02.003 · Cited by 39 · see citing works

Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors: Design, synthesis, cytotoxicity, and MDR reversal activities

Shawky, A. M., Abdalla, A. N., Ibrahim, N. A., Abourehab, M. A. S., & Gouda, A. M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113403 · Cited by 39 · see citing works

Inhibition of ABCG2 transporter by lapatinib enhances 5-aminolevulinic acid-mediated protoporphyrin IX fluorescence and photodynamic therapy response in human glioma cell lines

Mansi, M., Howley, R., Chandratre, S., & Chen, B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115031 · Cited by 38 · see citing works

A curated binary pattern multitarget dataset of focused ATP-binding cassette transporter inhibitors

Stefan, S. M., Jansson, P. J., Pahnke, J., & Namasivayam, V. (2022) · Scientific Data · doi:10.1038/s41597-022-01506-z · Cited by 37 · see citing works

Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects

Lei, Y.-R., He, X., Li, J., & Mo, C. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902052 · Cited by 37 · see citing works

Re-evaluation of the hCMEC/D3 based in vitro BBB model for ABC transporter studies

Balzer, V., Poc, P., Puris, E., Martin, S., Aliasgari, M., Auriola, S. O. K., & Fricker, G. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.02.017 · Cited by 36 · see citing works

Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP)

Antoni, F., Bause, M., Scholler, M., Bauer, S., Stark, S., Jackson, S. M., Manolaridis, I., Locher, K. P., König, B., Buschauer, A., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112133 · Cited by 35 · see citing works

Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles

Kita, D. H., Guragossian, N., Zattoni, I. F., Moure, V. R., Rego, F. G. D. M., Lusvarghi, S., Moulenat, T., Belhani, B., Picheth, G., Bouacida, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79892-w · Cited by 35 · see citing works

Structure of the Human Cholesterol Transporter ABCG1

Skarda, L., Kowal, J., & Locher, K. P. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167218 · Cited by 35 · see citing works

Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development

Moinul, M., Amin, S. A., Jha, T., & Gayen, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114628 · Cited by 34 · see citing works

5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy

Howley, R., Chandratre, S., & Chen, B. (2023) · Bioengineering · doi:10.3390/bioengineering10040496 · Cited by 33 · see citing works

The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP

Ambjørner, S. E. B., Wiese, M., Köhler, S. C., Svindt, J., Lund, X. L., Gajhede, M., Saaby, L., Brodin, B., Rump, S., Weigt, H., et al. (2020) · Cells · doi:10.3390/cells9030613 · Cited by 31 · see citing works

New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2

Pires, A. D. R. A., Lecerf-Schmidt, F., Guragossian, N., Pazinato, J., Gozzi, G. J., Winter, E., Valdameri, G., Veale, A., Boumendjel, A., Pietro, A. D., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.053 · Cited by 30 · see citing works

Targeting ABCG2 transporter to enhance 5-aminolevulinic acid for tumor visualization and photodynamic therapy

Chandratre, S., Olsen, J., Howley, R., & Chen, B. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115851 · Cited by 30 · see citing works

Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881

Zhang, Y., Zhang, X., Zhang, G.-N., Wang, Y., Huizhong, X., Zhang, D., Shukla, S., Liu, L., Yang, D., Ambudkar, S. V., et al. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.02.019 · Cited by 29 · see citing works

ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

Liu, C., Xing, W., Yu, H., Zhang, W., & Si, T. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01800-7 · Cited by 28 · see citing works

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study

Wu, Z., Teng, Q., Yang, Y., Acharekar, N., Wang, J., He, M. Y., Yoganathan, S., Lin, J., Wang, J., & Chen, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.018 · Cited by 25 · see citing works

Contrasting roles of the ABCG2 Q141K variant in prostate cancer

Sobek, K. M., Cummings, J. L., Bacich, D. J., & O’Keefe, D. S. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.020 · Cited by 25 · see citing works

Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors

Bicker, J., Fortuna, A. C., Alves, G., Soares-da-Silva, P., & Falcão, A. C. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.077883 · Cited by 24 · see citing works

Application of fluorescence correlation spectroscopy to study substrate binding in styrene maleic acid lipid copolymer encapsulated ABCG2

Horsey, A. J., Briggs, D. A., Holliday, N. D., Briddon, S. J., & Kerr, I. D. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183218 · Cited by 22 · see citing works

Tetrahydroquinoline/4,5‐Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2)

Vesga, L. C., Kronenberger, T., Tonduru, A. K., Kita, D. H., Zattoni, I. F., Bernal, C. C., Bohórquez, A. R. R., Méndez‐Sánchez, S. C., Ambudkar, S. V., Valdameri, G., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100188 · Cited by 20 · see citing works

Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment

LUSTIG, S. D., KODALI, S. K., Longo, S. L., Kundu, S., & Viapiano, M. S. (2022) · Anticancer Research · doi:10.21873/anticanres.15530 · Cited by 19 · see citing works

A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2)

Zattoni, I. F., Kronenberger, T., Kita, D. H., Guanaes, L. D., Guimarães, M. M., Prado, L. D. O., Ziasch, M., Vesga, L. C., Rego, F. G. D. M., Picheth, G., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109718 · Cited by 18 · see citing works

Fluorescence-based methods for studying activity and drug-drug interactions of hepatic solute carrier and ATP binding cassette proteins involved in ADME-Tox

Özvegy‐Laczka, C., Ungvári, O., & Bakos, É. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115448 · Cited by 18 · see citing works

Structural View of Cryo-Electron Microscopy-Determined ATP-Binding Cassette Transporters in Human Multidrug Resistance

Fan, W., Shao, K., & Luo, M. (2024) · Biomolecules · doi:10.3390/biom14020231 · Cited by 18 · see citing works

Effects of Various Pharmaceutical Excipients on the Intestinal Transport and Absorption of Sulfasalazine, a Typical Substrate of Breast Cancer Resistance Protein Transporter

Sawangrat, K., Morishita, M., Kusamori, K., Katsumi, H., Sakane, T., & Yamamoto, A. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.07.011 · Cited by 18 · see citing works

In Silico Identification and In Vitro Evaluation of New ABCG2 Transporter Inhibitors as Potential Anticancer Agents

Micco, S. D., Sarno, V. D., Rossi, M., Vestuto, V., Konno, T., Novi, S., Tecce, M. F., Napolitano, V., Ciaglia, T., Vitale, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010725 · Cited by 17 · see citing works

In Vitro and In Vivo Evaluation of ABCG2 (BCRP) Inhibitors Derived from Ko143

Zechner, M., Jaramillo, C. A. C., Zubler, N. S., Taddio, M. F., Mu, L., Altmann, K., & Krämer, S. D. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00168 · Cited by 17 · see citing works

Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter

Köhler, S. C., Silbermann, K., & Wiese, M. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.010 · Cited by 17 · see citing works

Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins

Shen, H., Yao, M., Sinz, M., Marathe, P., Rodrigues, A. D., & Zhu, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00472 · Cited by 17 · see citing works

Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats

Rowbottom, C., Pietrasiewicz, A., Tuczewycz, T., Grater, R., Qiu, D., Kapadnis, S., & Trapa, P. E. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.740 · Cited by 16 · see citing works

Small molecule kinase inhibitors enhance aminolevulinic acid-mediated protoporphyrin IX fluorescence and PDT response in triple negative breast cancer cell lines

Palasuberniam, P., Kraus, D., Mansi, M. S., Howley, R., Braun, A., Myers, K. A., & Chen, B. (2021) · Journal of Biomedical Optics · doi:10.1117/1.jbo.26.9.098002 · Cited by 16 · see citing works

Modulation of ABCG2 Transporter Activity by Ko143 Derivatives

Yu, Q., Dehghani‐Ghahnaviyeh, S., Rasouli, A., Sadurní, A., Kowal, J., Bang-Sørensen, R., Wen, P., Zechner, M., Irobalieva, R. N., Ni, D., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00353 · Cited by 15 · see citing works

Total hepatocellular disposition profiling of rosuvastatin and pitavastatin in sandwich-cultured human hepatocytes

Kanda, K., Takahashi, R., Yoshikado, T., & Sugiyama, Y. (2018) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2018.04.001 · Cited by 15 · see citing works

The effect of green tea catechins on breast cancer resistance protein activity and intestinal efflux of aflatoxin B1 via breast cancer resistance protein in Caco-2 cells

Tuntiteerawit, P., Jarukamjorn, K., & Porasuphatana, S. (2020) · Toxicological Research · doi:10.1007/s43188-019-00032-2 · Cited by 15 · see citing works

Predictors of therapeutic efficacy of 5-aminolevulinic acid-based photodynamic therapy in human prostate cancer

Yamamoto, S., Fukuhara, H., Seki, H., Kawada, C., Nakayama, T., Karashima, T., Ogura, S., & Inoue, K. (2021) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2021.102452 · Cited by 15 · see citing works

Sulfonation of raloxifene in HEK293 cells overexpressing SULT1A3: Involvement of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in excretion of sulfate metabolites

Zhou, X., Wang, S., Sun, H., & Wu, B. (2015) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2015.09.001 · Cited by 15 · see citing works

Structural Basis of the Allosteric Inhibition of Human ABCG2 by Nanobodies

Irobalieva, R. N., Manolaridis, I., Jackson, S. M., Ni, D., Pardon, E., Stahlberg, H., Steyaert, J., & Locher, K. P. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168234 · Cited by 13 · see citing works

AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer

Liu, K., Li, Y.-C., Chen, Y., Shi, X., Xing, Z.-H., He, Z.-J., Wang, S.-T., Liu, W., Zhang, P.-W., Yu, Z.-Z., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.680663 · Cited by 13 · see citing works

EXPRESSION OF CONCERN: Photodynamic therapy with 5‐aminolaevulinic acid and DNA damage: unravelling roles of p53 and ABCG 2

Postiglione, I., Barra, F., Aloj, S. M., & Palumbo, G. A. (2016) · Cell Proliferation · doi:10.1111/cpr.12274 · Cited by 13 · see citing works

A Synthetic Hybrid Molecule for the Selective Removal of Human Pluripotent Stem Cells from Cell Mixtures.

Mao, D., Ando, S., Sato, S.-I., Qin, Y., Hirata, N., Katsuda, Y., Kawase, E., Kuo, T., Minami, I., Shiba, Y., et al. (2017) · Angewandte Chemie · doi:10.1002/anie.201610284 · Cited by 12 · see citing works

Application of JC1 for non-toxic isolation of cells with MDR transporter activity by flow cytometry

Wolosin, J. M., Zamudio, A. C., & Wang, Z. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174905 · Cited by 13 · see citing works

Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain

Strope, J. D., Peer, C. J., Sissung, T. M., Hall, O. M., Huang, P. A., Harris, E. M., Gustafson, K. R., Henrich, C. J., Sigano, D. M., Pauly, G. T., et al. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1683324 · Cited by 13 · see citing works

Repurposing the Tyrosine Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Cancer Therapy: A Comprehensive Review

Boichuk, S., & Gessel, T. (2025) · Cancers · doi:10.3390/cancers17203354 · Cited by 12 · see citing works

Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors

Zhu, J., Lei, S., Lu, J. L., Hao, Y., Qian, Q., Devanathan, A. S., Feng, Z., Xie, X., Wipf, P., & Ma, X. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115666 · Cited by 12 · see citing works

Combinatorial Anticancer Drug Screen Identifies Off-Target Effects of Epigenetic Chemical Probes

Barghout, S. H., Mann, M. K., Aman, A. M., Yu, Y., Alteen, M. G., Schimmer, A. D., Schapira, M., Arrowsmith, C. H., & Baršytė-Lovejoy, D. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00451 · Cited by 12 · see citing works

Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability

Cai, C., Teng, Q., Murakami, M., Ambudkar, S. V., Chen, Z., & Korlipara, V. L. (2023) · Biomolecules · doi:10.3390/biom13020253 · Cited by 11 · see citing works

Effectiveness of lapatinib for enhancing 5‐aminolevulinic acid‐mediated protoporphyrin IX fluorescence and photodynamic therapy in human cancer cell lines with varied ABCG2 activities

Howley, R., Olsen, J., & Chen, B. (2024) · Photochemistry and Photobiology · doi:10.1111/php.13936 · Cited by 11 · see citing works

Fumitremorgins and Relatives – From Tremorgenic Compounds to Valuable Anti-Cancer Drugs

Abraham, W. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170724103410 · Cited by 11 · see citing works

The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs

Wu, C., Murakami, M., Wu, Y., Lin, C., Li, Y., Huang, Y.-H., Hung, T., & Ambudkar, S. V. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112922 · Cited by 11 · see citing works

The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance

Narayanan, S., Wu, Z., Wang, J., Ma, H., Acharekar, N., Koya, J., Yoganathan, S., Fang, S., Chen, Z., & Pan, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.61229 · Cited by 10 · see citing works

Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein

Song, J. G., Lee, Y. S., Park, J.-A., Lee, E.-H., Lim, S., Yang, S. J., Zhao, M., Lee, K., & Han, H. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3127-2 · Cited by 10 · see citing works

Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban

Jacqueroux, E., Hodin, S., Saïb, S., Hé, Z., Bin, V., Delézay, O., & Delavenne, X. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.01.002 · Cited by 10 · see citing works

Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier

Kumar, J. S., Wei, B., Madigan, J. P., Simpson, R. J., Hall, M. D., & Gottesman, M. M. (2016) · Scientific Reports · doi:10.1038/srep20418 · Cited by 10 · see citing works

The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

Wu, C., Li, Y., Chi, Y.-C., Huang, Y.-H., Hung, T., & Wu, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179440 · Cited by 9 · see citing works

The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration

Ito, F., Miura, M., Fujioka, Y., Abumiya, M., Kobayashi, T., Takahashi, S., Yoshioka, T., Kameoka, Y., & Takahashi, N. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-03000-x · Cited by 9 · see citing works

What makes the α1A‐adrenoceptor gene product assume an α1L‐adrenoceptor phenotype?

White, C. W., da Silva, E. D., Lim, L., & Ventura, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14599 · Cited by 9 · see citing works

A Combination of Clioquinol, Zinc and Copper Increases the Abundance and Function of Breast Cancer Resistance Protein in Human Brain Microvascular Endothelial Cells

Yap, C., Short, J. L., & Nicolazzo, J. A. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.04.010 · Cited by 8 · see citing works

A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo

Kokubo, S., Ohnuma, S., Murakami, M., Kikuchi, H., Funayama, S., Suzuki, H., Kajiwara, T., Yamamura, A., Karasawa, H., Sugisawa, N., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212502 · Cited by 8 · see citing works

Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP)

Liao, M., Chuang, B.-C., Zhu, Q. L., Li, Y., Guan, E., Yu, S., Yang, J. J., Prakash, S. R., & Xia, C. Q. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1328147 · Cited by 8 · see citing works

Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2

Lin, B.-H., Li, Y.-C., Murakami, M., Wu, Y., Huang, Y.-H., Hung, T., Ambudkar, S. V., & Wu, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117542 · Cited by 7 · see citing works

Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier

Sun, A., & Wang, J. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03598-7 · Cited by 7 · see citing works

Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2)

Zanzarini, I. D. S., Kita, D. H., Scheiffer, G., dos Santos, K. K., Dutra, J. D. P., Pastore, M. A., Rego, F. G. D. M., Picheth, G., Ambudkar, S. V., Pulvirenti, L., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107283 · Cited by 7 · see citing works

The role of ABC-transporters in homeostasis, cancer pathogenesis and therapy

Boichuk, S., & Ivoilova, T. V. (2024) · Advances in molecular oncology · doi:10.17650/2313-805x-2024-11-1-8-21 · Cited by 7 · see citing works

A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells

Guo, C., Liu, F., Qi, J., Ma, J., Lin, S., Zhang, C., Zhang, Q., Zhang, H., Lu, R., & Li, X. (2018) · Molecules · doi:10.3390/molecules23123264 · Cited by 7 · see citing works

The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2

Wu, C., Hsieh, Y., Tseng, H.-Y., Huang, Y.-H., Li, Y., Hung, T., Wang, S.-P., & Wu, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113663 · Cited by 7 · see citing works

Modulation of ABCG2 Transporter Activity by Ko143 Derivatives

Yu, Q., Dehghani‐Ghahnaviyeh, S., Rasouli, A., Sadurní, A., Kowal, J., Bang-Sørensen, R., Wen, P., Zechner, M., Irobalieva, R. N., Ni, D., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00353 · Cited by 15 · see citing works

Structural basis of small-molecule inhibition of human multidrug transporter ABCG2

Jackson, S. M., Manolaridis, I., Kowal, J., Zechner, M., Taylor, N. M. I., Bause, M., Bauer, S., Bartholomäus, R., Bernhardt, G., König, B., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0049-1 · Cited by 325 · see citing works

Can an inhibitor of a multidrug pump become a substrate?

Hutchison, E. (2022) · Nottingham ePrints (University of Nottingham)

A time-resolved Förster resonance energy transfer assay to investigate inhibitor binding to ABCG2Preprint

Mitchell, J., Briggs, D. A., Mistry, S. J., Mbiwan, H. A., Kellam, B., Holliday, N. D., Briddon, S. J., & Kerr, I. D. (2023) · Repository@Nottingham (University of Nottingham)

A time-resolved Förster resonance energy transfer assay to investigate drug and inhibitor binding to ABCG2

Mitchell, J., Briggs, D. A., Mistry, S. J., Mbiwan, H. A., Kellam, B., Holliday, N. D., Briddon, S. J., & Kerr, I. D. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.109915 · Cited by 1 · see citing works